Anti-retroviral (ARV) drug resistance in patients with second therapeutic failure in an HIV program, Colombia
##plugins.themes.bootstrap3.article.sidebar##
PDF (Español (España))
FLIP
HTML (Español (España))
##plugins.themes.bootstrap3.article.main##
Objective. To make a description of ARV drugs in patients with second therapeutic failure in an HIV Program between January and December, 2011. Materials and methods. Adescriptive, retrospective case series study was conducted. It was made a description of HIV mutations, clinical characteristics and laboratory findings of patients with resistance in second therapeutic failure. Results. 30 patients with second therapeutic failure were identified in the study period. The average time of use of ARV therapy per patient was 77.2 (SD = 56). 12 patients underwent three changes of ARV months shema per therapeutic failure and 2 other patients up to four changes of schema. Most frequent mutations were the primary to Protease inhibitors (M46I, I54V, L101) and to inhibitors of Reverse analog Transcriptase of Nucleoside. (Abacavir, Didanosine and Zidovudine, Stavudine).
Downloads
##plugins.themes.bootstrap3.article.details##
Pneumocystis pneumonia - Los Angeles. MMWR Morb Mortal Wkly Rep, 1981. 30(21):250-2.
Barre-Sinoussi, F., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 1983. 220(4599): 868-71.
Fischl, M.A., et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med, 1987. 317(4):185-91.
Metzner, K.J., et al. Minority quasispecies of drugresistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis, 2009. 48(2):239-47.
Erice A, M.S., Gatell JM. Significado clínico de la resistencia del VIH a los anti-rretrovirales, in Resistencia del VIH a los fármacos anti-rretrovirales. E. Antares, Editor. Barcelona. 1999. 123-131.
Afani S, A., et al. Resistencia primaria a terapia antirretroviral en pacientes con infección por VIH/SIDA en Chile. Revista médica de Chile, 2005. 133:295-301.
Kuritzkes, D.R., et al. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J Acquir Immune Defic Syndr, 2004. 36(1):600-3.
